fluticasone

(redirected from Fluticasone proprionate)
Also found in: Dictionary.

fluticasone

 [floo-tik´ah-sōn″]
a steroid antiinflammatory agent, used as the propionate salt topically in treatment of itching or inflammation, intranasally for allergic rhinitis and other inflammatory nasal conditions, and nasal polyps, and by inhalation in treatment of asthma.

fluticasone

/flu·tic·a·sone/ (floo-tik´ah-sōn″) a synthetic corticosteroid used as the propionate salt to treat inflammation in certain dermatoses, allergic rhinitis and other inflammatory nasal conditions, nasal polyps, and asthma.

fluticasone

[floo͡tik′äsōn′]
a steroid antiinflammatory agent, used topically as the propionate salt in treatment of itching or inflammation, intranasally in the treatment of allergic rhinitis and other inflammatory nasal conditions and of nasal polyps, and by inhalation in treatment of asthma.

fluticasone

A CORTICOSTEROID drug used as an inhalant to treat ASTHMA and hay fever. Extensive studies have shown that fluticasone is safe and effective and, in the recommended dosage, does not affect growth in childhood. Brand names are Flixonase (nasal spray), Flixotide (inhaler) and, for external use only, Cutivate. With SALMETEROL it is marketed as Seretide.
References in periodicals archive ?
In all studies greater improvements in lung function were observed with a lower total daily dose of FF compared to fluticasone proprionate (FP).
This physiologic skin barrier repair cream proved itself the equal of fluticasone proprionate cream (Cutivate) in a 113-patient multicenter randomized head-to-head comparison, Dr.
Use of fluticasone proprionate did increase the risk of pneumonia.
for the relief of symptoms of seasonal allergic rhinitis (SAR) in patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone proprionate for symptomatic relief.
In the data presented by Pulmatrix at ISAM, two mouse models of allergic asthma, the ovalbumin (OVA) model and house dust mite (HDM) model, were used to show the utility of Pulmatrix's iSPERSE platform using a well-described inhaled combination, a long acting bronchodilator, salmeterol xinafoate (SX), and a corticosteroid, fluticasone proprionate (FP).